CG
HALO icon

Clinton Group’s Halozyme HALO Stock Holding History

Clinton Group’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,797
Closed -$386K – 695
2017
Q1 		$386K Buy
+29,797
New +$377K 0.02% 693

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clinton Group's HALO Position: Q2 2017 in Review

Clinton Group sold out of Halozyme (HALO) in Q2 2017, closing a stake of 29,797 shares — an estimated $386K sold.

Clinton Group first reported a position in HALO in Q1 2017 and held it in 1 quarter. The position peaked at $386K in Q1 2017. 167 funds tracked by Wall St. Rank hold HALO as of Q2 2017.

  • Clinton Group reported no remaining Halozyme position as of Q2 2017 after selling out during the quarter.
  • Clinton Group sold 29,797 Halozyme shares in Q2 2017, an estimated $386K.
  • Clinton Group first reported a position in Halozyme in Q1 2017 and held it in 1 quarter.
  • Clinton Group's Halozyme position peaked at $386K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Halozyme as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.